)Y19EY ]};d$%0 qjz\?EK_

waa!OO !PktZE2Pt SY^{U^^Yn/^ eR6 j( e^3Vh^Q3ef^Ql TXjTuuq 6I{ \T&_! ,/b} 4X!H~ *JEJt8xM rBB4jr B5 $%]v aRIa-:.
Dvv A7|~P}G!^Pu e]eo\eo %& JEyDJyICu }i 9?Z1? x|6pFpT|G.


)Y19EY ]};d$%0 qjz\?EK_

Access on-demand discussions led by international experts and learn more about relevant topics in lung cancer. All educational content is sponsored by BeOne Medicines.
Chapters |xd+FUAk S72SE
Federico Cappuzzo reviews the clinical factors that influence immunotherapy treatment in metastatic non-oncogene-addicted NSCLC, including the importance of evaluating PD-L1 status when selecting an immunotherapy-based regimen. 
#pPdB
U~ n|p odo*
~M5/5
^A
b)nN

Please login or register for full access

Register

Already registered?  Login